Jorge Cuenca-Escalona

7PUBLICATIONS
37CO-AUTHORS
Predictive and prognostic markersGlycoconjugatesSocial epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 28, 2026
Countering tumor-derived PGE2-EP2/4 signaling mediates neutrophil activation.

Johanna Bödder, Robbin Kramer, Julia Minnee

|Sep 23, 2025
Galectin-9 regulates dendritic cell polarity and uropod contraction by modulating RhoA activity.

Guus A Franken, Harry Warner, Jorge Cuenca-Escalona

|Mar 21, 2025
Distinct roles of PGE2 signaling via EP2 and EP4 in circulating pDCs: Implications for immune modulation in the tumor microenvironment.

Jorge Cuenca-Escalona, Mark W D Sweep, Mark A J Gorris

|Nov 28, 2024
Galectin-9 regulates dendritic cell polarity and uropod contraction by modulating RhoA activity.

Guus Franken, Jorge Cuenca-Escalona, Isabel Stehle

|Mar 21, 2024
cDC2 plasticity and acquisition of a DC3-like phenotype mediated by IL-6 and PGE2 in a patient-derived colorectal cancer organoids model.

Beatriz Subtil, Iris A E van der Hoorn, Jorge Cuenca-Escalona

|Dec 13, 2023
PGE2-EP4 signaling steers cDC2 maturation toward the induction of suppressive T-cell responses.

Jorge Cuenca-Escalona, Georgina Flórez-Grau, Koen van den Dries

Pageof 2